Home | Welcome to Contract Pharma   
Last Updated Tuesday, May 26 2015


Financial Reports: Merck & Co.

By Gil Roth

Published July 30, 2013
Merck 2Q13

2Q Revenues: $11.0 billion (-11%)

2Q Earnings: $906 million (-50%)

YTD Revenues: $21.7 billion (-10%)

YTD Earnings: $2.5 billion (-29%)

Comments: An 80% drop in Singulair sales led to a $1.1 billion shortfall in revenues for Merck in 2Q13, wiping out scant gains for top products Januvia (+1% to $1.1 billion), Zetia (+3% to $650 million), Remicade (+2% to $527 million) and Janumet (+16% to $474 million). A stronger dollar also hurt Januvia revenues, which would have posted 7% growth at constant exchange rates. For YTD, Januvia sales are down 1% to $2.0 billion, while Janumet sales are up 10% to $802 million. Consumer Care revenues fell 11% to $490 million in the quarter, after the termination of some distribution arrangements in China and a reversal of sales previously made to its distributors.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On